Highlights of This Issue 6081

SPECIAL FEATURES

CCR Translations

6083 Real-time Pathology to Guide Breast Surgery: Seeing Alone Is Not Believing
Irving J. Bigio
See article p. 6315

6086 Regulatory T Cells Move in When Gliomas Say "I DO"
Bryan D. Choi, Peter E. Fecci, and John H. Sampson
See article p. 6110

Molecular Pathways

6089 Molecular Pathways: The Metabolic Regulator Estrogen-Related Receptor \( \alpha \) as a Therapeutic Target in Cancer
Ching-yi Chang and Donald P. McDonnell

6096 Molecular Pathways: Regulation of Metabolism by RB
Brian F. Clem and Jason Chesney

Review

6101 Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop

HUMAN CANCER BIOLOGY

6110 IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Derek A. Wainwright, Irina V. Balyasnikova, Alan L. Chang, Atique U. Ahmed, Kyung-Sub Moon, Brenda Auffinger, Alex L. Tobias, Yu Han, and Maciej S. Lesniak
See commentary p. 6086

Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma

Expression Profiling of Archival Tumors for Long-term Health Studies
Levi Waldron, Shuji Ogino, Yujin Hoshida, Koart Shimia, Amy E. McCarty Reed, Peter T. Simpson, Yoshifumi Baba, Katsuhiko Nosho, Nicola Segata, Ana Cristina Vargas, Margaret C. Cummings, Sunil R. Lakhan, Gregory J. Kirkner, Edward Giovannucci, John Quackenbush, Todd R. Golub, Charles S. Fuchs, Giovanni Parmigiani, and Curtis Huttenhower

Decreased NK Cells in Patients with Head and Neck Cancer Determined in Archival DNA

Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
Kelly Boucher, Nancy Parquet, Raymond Widen, Kenneth Shain, Rachid Baz, Melissa Alsina, John Koomen, Claudio Anasetti, William Dalton, and Lia E. Perez

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan, Ronglai Shen, Daphne C. Ang, Melissa L. Johnson, Sandra P. D’Angelo, Paul K. Paik, Edyta B. Brzostowski, Gregory J. Biely, Mark G. Kris, Maureen E. Zakowski, and Marc Ladanyi

Establishment and Characterization of Novel Cell Lines from Sinonasal Undifferentiated Carcinoma
Yoko Takahashi, Michael E. Kuperman, Diana Bell, Tilahun Jiffar, June Goo Lee, Tong-Xin Xie, Ning-Wei Li, Mei Zhao, Mitchell J. Frederick, Alexander Gelbard, Jeffrey N. Myers, and Ehab Y. Hanna
### Overexpression of Ecdysoneless in Pancreatic Cancer and Its Role in Oncogenesis by Regulating Glycolysis


### Proliferation in the Normal FTE Is a Hallmark of the Follicular Phase, Not BRCA Mutation Status

Sophia H.L. George, Anca Milea, and Patricia A. Shaw

### Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies

Eliane Fischer, Krishna Chaitanya, Thomas Wuest, Andrew M. Scott, Maries van den Broek, Roger Schibli, Stefan Bauer, and Christoph Renner

### Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Junko Tanizaki, Isamu Okamoto, Takafumi Okabe, Kazuko Sakai, Kaoru Tanaka, Hidetoshi Hayashi, Hiroyasu Kaneda, Ken Takezawa, Kiyoko Kuvata, Haruka Yamaguchi, Erina Hatashita, Kazuto Nishio, and Kazuhiiko Nakagawa

### Superior Efficacy of a Combined Epigeneic Therapy against Human Mantle Cell Lymphoma Cells

Warren Fiskus, Rekha Rao, Ramesh Balusu, Siddhartha Ganguly, Jianguo Tao, Eduardo Sotomayor, Uma Mudumuru, Jacqueline E. Smith, Stacey L. Hembruff, Peter Atadja, Victor E. Marquez, and Kapil Bhalla

### Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier


---

### In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-Cell Antitumor Cytotoxicity through ICAM-1 Engagement

Ismahene Benzaid, Hannu Mönkkönen, Edith Bonneye, Jukka Mönkkönen, and Philippe Clézardin

### Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: *In Vitro* and *In Vivo* Evidence

Maria T. Di Martino, Emanuela Leone, Nicola Amadio, Umberto Foresta, Marta Lionetti, Maria R. Pitarri, Maria E. Gallo Cantafio, Annamaria Guilla, Francesco Conforti, Eugenio Morelli, Vera Tomai, Marco Rossi, Massimo Negri, Manlio Ferrarini, Michele Caraglia, Massoud A. Shammas, Nikhil C. Munshi, Kenneth C. Anderson, Antonino Neri, Pierosandro Tagliaferri, and Pierfrancesco Tassone

### TRAIL and Noxa Are Selectively Upregulated in Prostate Cancer Cells Downstream of the RIG-1/MAVS Signaling Pathway by Nonreplicating Sendai Virus Particles

Taeko Matsushima-Miyagi, Koji Hatano, Motonari Nomura, Liu Li-Wen, Tomoyuki Nishikawa, Kotaro Saga, Takashi Shimbo, and Yasufumi Kaneda

### Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor

Magalie Dosset, Yann Godet, Charline Vauchy, Laurent Bezinaud, Yu Chun Lone, Christine Sedlik, Christelle Liard, Emeline Levionnois, Bertrand Clerc, Federico Sandoval, Etienne Daguindau, Simon Wain-Hobson, Eric Tartour, Pierre Langlade-Demoyen, Christophe Borg, and Olivier Adotévi

### Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in *MLL*-Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands

Wing Keung Chan, May Kung Sutherland, Ying Li, Jonathan Zalevsky, Sarah Schell, and Wing Leung
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6306</td>
<td>Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model</td>
<td>Arne R.M. van der Bilt, Anton G.T. Terwisscha van Scheltinga, Hetty Timmer-Bosscha, Carolien P. Schröder, Linda Pot, Jos G.W. Kosterink, Ate G.J. van der Zee, Marjolijn N. Lub-de Hooge, Steven de Jong, Elisabeth G.E. de Vries, and Anna K.L. Reyners</td>
</tr>
<tr>
<td>6315</td>
<td>Scatter Spectroscopic Imaging Distinguishes between Breast Pathologies in Tissues Relevant to Surgical Margin Assessment</td>
<td>Ashley M. Laughney, Venkataramanan Krishnaswamy, Elizabeth J. Rizzo, Mary C. Schwab, Richard J. Barth, Brian W. Pogue, Keith D. Paulsen, and Wendy A. Wells</td>
</tr>
<tr>
<td>6326</td>
<td>Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer</td>
<td>Shunsuke Kondo, Satoshi Iwata, Takeko Yamada, Yusuke Inoue, Hiromi Ichihara, Yoshiko Kichikawa, Tomoki Katayose, Akiko Souta-Kuribara, Hiroto Yamazaki, Osamu Hosono, Hiroshi Kawasaki, Hiroto Tanaka, Yuichiro Hayashi, Michiie Sakamoto, Kazunori Kamiya, Nam H. Dang, and Chikao Morimoto</td>
</tr>
<tr>
<td>6339</td>
<td>Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors</td>
<td>Shinichi Yachida, Catherine M. White, Yoshiki Naito, Yi Zhong, Jacqueline A. Brosnan, Anne M. Macgregor-Das, Richard A. Morgan, Tyler Saunders, Daniel A. Laheru, Joseph M. Herman, Ralph H. Hruban, Alison P. Klein, Sian Jones, Victor Velculescu, Christopher L. Wolfgang, and Christine A. Ichouziu-Donahue</td>
</tr>
<tr>
<td>6348</td>
<td>Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients</td>
<td>Janet E. Brown, Richard J. Cook, Allan Lipton, and Robert E. Coleman</td>
</tr>
<tr>
<td>6356</td>
<td>Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009</td>
<td>Filip Janku, Donald A. Berry, Jing Gong, Henrique A. Parsons, David J. Stewart, and Razelle Kurzrock</td>
</tr>
<tr>
<td>6364</td>
<td>Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788</td>
<td>Jose Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Frederico Rojo, Joseph Taberner, Clifford DiLea, William Mietlowksi, Christie Low, Jerry Huang, Margaret Dugan, Kathryn Parker, Eric Walk, Allan van Oosterom, Erika Martinelli, and Chris H. Takimoto</td>
</tr>
<tr>
<td>6373</td>
<td>Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative</td>
<td>Apostolía-Maria Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqin Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Rajyalakshmi Luthra, Yang Ye, Sijin Wen, Donald Berry, and Razelle Kurzrock</td>
</tr>
<tr>
<td>6384</td>
<td>Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab</td>
<td>David O. Bates, Paul J. Catalano, Kirsty E. Symonds, Alex H.B. Varey, Pramila Ramani, Peter J. O'Dwyer, Bruce J. Giontonio, Neal J. Meropol, Al Bowen Benson, and Steven J. Harper</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

Replication-incompetent Sendai virus particles were injected into orthotopic prostate cancers in NOD-SCID mice on day 29 after the inoculation of human prostate cancer PC3 cells. The dual 4',6-diamidino-2-phenylindole (blue) and terminal deoxynucleotidyltransferase–mediated dUTP nick-end labeling (DAPI; green) staining showed that the TUNEL-positive apoptotic cells were dramatically increased in tumor regions. For details, see the article by Matsushima-Miyagi and colleagues on page 6271 of this issue.